Early destruction of tumor vasculature in tumor necrosis factor-α-based isolated limb perfusion is responsible for tumor response

Anti-Cancer Drugs

Volumn 17, Issue 8, 2006, Pages 949-959

  Hoving, Saske ^a   Seynhaeve, Ann L B ^a   Van Tiel, Sandra T ^a   Aan De Wiel Ambagtsheer, Gisela ^a   De Bruijn, Ernst A ^b   Eggermont, Alexander M M ^a   Ten Hagen, Timo L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apoptosis; Interstitial fluid pressure; Isolated limb perfusion; Leukocyte infiltration; Tumor necrosis factor ; Vascular damage

Indexed keywords

CYTOKINE; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MELPHALAN; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CELL INFILTRATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TISSUE LEVEL; DRUG UPTAKE; ERYTHROCYTE; EXTRAVASATION; HISTOPATHOLOGY; IC 50; LEUKOCYTE; LIMB PERFUSION; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SOFT TISSUE SARCOMA; TISSUE PRESSURE; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPILLARY PERMEABILITY; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CYTOKINES; HINDLIMB; HUMANS; LEUKOCYTES; MACROPHAGES; MALE; MELPHALAN; MODELS, ANIMAL; RATS; RATS, INBRED BN; SARCOMA, EXPERIMENTAL; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748473423     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000224450.54447.b3     Document Type: Article

References (32)

1. Eggermont AM, de Wilt JH, Ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003; 4:429-437.
2. Grunhagen DJ, de Wilt JH, Ten Hagen TL, Eggermont AM. Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006; 3:94-103.
3. Nooijen PT, Eggermont AM, Schalkwijk L, Henzen-Logmans S, de Waal RM, Ruiter DJ. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res 1998; 58:4880-4887.
4. Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer 1994; 57:656-663.
5. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg 1996; 83:551-555.
6. de Wilt JH, Manusama ER, van Tiel ST, van IJken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer 1999; 80:161-166.
7. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, et al. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer 1996; 74:1908-1915.
8. Manusama ER, Nooijen PT, Stavast J, de Wilt JH, Marquet RL, Eggermont AM. Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats. J Surg Res 1998; 78:169-175.
9. Klimp AH, de Vries EG, Scherphof GL, Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002; 44:143-161.
10. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24:392-407.
11. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16:21-26.
12. UKCCCR. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998; 77:1-10.
13. Kramer SM, Carver ME. Serum-free in vitro bioassay for the detection of tumor necrosis factor. J Immunol Methods 1986; 93:201-206.
14. Tjaden UR, De Bruijn EA. Chromatographic analysis of anticancer drugs. J Chromatogr 1990; 531:235-294.
15. Fadnes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res 1977; 14:27-36.
16. Brunstein F, Hoving S, Seynhaeve AL, van Tiel ST, Guetens G, de Bruijn EA, et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J Natl Cancer Inst 2004; 96:1603-1610.
17. Seynhaeve AL, Vermeulen CE, Eggermont AM, Ten Hagen TL. Cytokines and vascular permeability: an in vitro study on human endothelial cells in relation to tumor necrosis factor-alpha-primed peripheral blood mononuclear cells. Cell Biochem Biophys 2006; 44:157-169.
18. Kristensen CA, Nozue M, Boucher Y, Jain RK. Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer 1996; 74:533-536.
19. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res 1995; 15:219-223.
20. Hoving S, Brunstein F, Aan dW-A, van Tiel ST, de Boeck G, de Bruijn EA, et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res 2005; 65:4300-4308.
21. Manusama ER, Stavast J, Durante NM, Marquet RL, Eggermont AM. Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach. Eur J Surg Oncol 1996; 22:152-157.
22. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82:973-980.
23. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 1997; 79: 1129-1137.
24. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4:408-414.
25. Dumez H, Guetens G, de Boeck G, Highley MS, De Bruijn EA, Van Oosterom AT, Maes RA. In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender. Anticancer Drugs 2005; 16:885-891.
26. Millan CG, Marinero ML, Castaneda AZ, Lanao JM. Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 2004; 95:27-49.
27. -/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport. Int J Cancer 2002; 99:514-519.
28. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
29. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257.
30. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys 1991; 20:287-289.
31. Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J Immunol Methods 2003; 280:1-11.
32. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer 2003; 107:317-322.